Long‐term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B

Publisher： John Wiley & Sons Inc

E-ISSN： 1478-3231|38|S1|84-89

ISSN： 1478-3223

Source： LIVER INTERNATIONAL (ELECTRONIC), Vol.38, Iss.S1, 2018-02, pp. : 84-89

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Reduced risk of relapse after long‐term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 9, 2015-05 ,pp. : 867-876

John Wiley & Sons Inc

Access to resources Recommend Favorite

Systematic review: cessation of long‐term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen‐negative chronic hepatitis B

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 3, 2015-08 ,pp. : 243-257

John Wiley & Sons Inc

Access to resources Recommend Favorite

HLA‐DP genes polymorphisms associate with hepatitis B surface antigen kinetics and seroclearance during nucleot(s)ide analogue therapy

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 4, 2015-04 ,pp. : 1290-1302

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long‐term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects

By  

HEPATOLOGY, Vol. 62, Iss. 3, 2015-09 ,pp. : 684-693

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety of long‐term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection

By  

HEPATOLOGY, Vol. 62, Iss. 1, 2015-07 ,pp. : 40-46

John Wiley & Sons Inc

Access to resources Recommend Favorite